Literature DB >> 17987654

A systematic review of prevalence studies of depression in Parkinson's disease.

Jennifer S A M Reijnders1, Uwe Ehrt, Wim E J Weber, Dag Aarsland, Albert F G Leentjens.   

Abstract

Prevalence rates of depressive disorders in Parkinson's disease (PD) vary widely across studies, ranging from 2.7% to more than 90%. The aim of this systematic review was to calculate average prevalences of depressive disorders taking into account the different settings and different diagnostic approaches of studies. Using Medline on Pubmed, a systematic literature search was carried out for studies of depression in Parkinson's disease. A total of 104 articles were included and assessed for quality; 51 articles fulfilled the quality criteria. Multiple publications from the same database were not included in the meta-analysis. In the remaining 36 articles, the weighted prevalence of major depressive disorder was 17% of PD patients, that of minor depression 22% and dysthymia 13%. Clinically significant depressive symptoms, irrespective of the presence of a DSM defined depressive disorder, were present in 35%. In studies using a (semi) structured interview to establish DSM criteria, the reported prevalence of major depressive disorder was 19%, while in studies using DSM criteria without a structured interview, the reported prevalence of major depressive disorder was 7%. Population studies report lower prevalence rates for both major depressive disorder and the clinically significant depressive symptoms than studies in other settings. This systematic review suggests that the average prevalence of major depressive disorder in PD is substantial, but lower than generally assumed. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 17987654     DOI: 10.1002/mds.21803

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  296 in total

Review 1.  Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism.

Authors:  Hong Jin; Jin-Ru Zhang; Yun Shen; Chun-Feng Liu
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

2.  Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease.

Authors:  Roseanne D Dobkin; Jade Tiu Rubino; Lesley A Allen; Jill Friedman; Michael A Gara; Margery H Mark; Matthew Menza
Journal:  J Consult Clin Psychol       Date:  2012-03-12

3.  Parkinson disease: Depression-risk factor or early symptom in Parkinson disease?

Authors:  Albert F Leentjens
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

Review 4.  [Parkinson's disease in the elderly].

Authors:  Rüdiger Lange; Frank Erbguth
Journal:  Z Gerontol Geriatr       Date:  2017-07-19       Impact factor: 1.281

Review 5.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 7.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 8.  VPS35 Parkinson's disease phenotype resembles the sporadic disease.

Authors:  Walter Struhal; Stefan Presslauer; Sabine Spielberger; Alexander Zimprich; Eduard Auff; Thomas Bruecke; Werner Poewe; Gerhard Ransmayr
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

10.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.